Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases.
Employees: 51-200
Founded date: 2018
Investors 2
| Date | Name | Website |
| - | Altium Cap... | altiumcap.... |
| - | Roivant | roivant.co... |
Mentions in press and media 7
| Date | Title | Description | Source |
| 30.04.2024 | HanAll Biopharma Reports Q1 2024 Financial Results and Provi... | Delivered solid performance to start 2024, with record-breaking first quarter revenue of 34.1 billio... | en.prnasia... |
| 21.03.2024 | HanAll Biopharma Reports Full-Year 2023 Financial Results an... | Full-year 2023 net revenue reaches 135 billion KRW, driven by strong sales growth. R&D momentum ... | en.prnasia... |
| 12.03.2024 | Immunovant Awarded U.S. Patent for IMVT-1402 | - | globenewsw... |
| 28.11.2023 | Today’s biotech news roundup, in under 800 words | Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech ne... | statnews.c... |
| 04.10.2022 | Immunovant Announces Pricing of $75.0 Million Underwritten O... | - | tcgcrossov... |
| 03.02.2021 | Immunovant plunges nearly 50% after pausing a trial for its ... | Shares of Immunovant plunged nearly 50% on Tuesday after the company announced a voluntary pause in ... | businessin... |
| - | A patient-focused approach to advancing CIDP treatment | As many as four percent of the world’s population lives with an autoimmune disease, in which the imm... | statnews.c... |